Effect of Metformin on Sleep Architecture in Patients with Comorbid Diabetes and Sleep Apnea
Abstract
Background: : / Objectives Patients with poor sleep are at high risk for developing diabetes (T2DM). Since T2DM is linked to increased risk of obstructive sleep apnea (OSA), and Metformin is commonly used to treat T2DM, we examined how Metformin affects sleep stages in patients with concurrent T2DM and OSA-related symptoms of snoring and fatigue. T2DM patients on Metformin, progressively develop increased insulin resistance associated with sleep disturbances, and poor glycemic control. We explored changes in sleep patterns in T2DM patients on Metformin. We explored if Metformin affects sleep Architecture in T2DM patients. Methods Evaluate PSG (polysomnogram data from T2DM patients on Metformin along with data on age, BMI and sex. Data to be analyzed as mean +SE and linear regression, t test p< 0.5 taken as significant. Results Non-obese patients taking Metformin experienced a significant decrease in REM duration compared to patients on alternative therapies (p = 0.036). There was no such change in REM for obese patients taking Metformin. While there was no change in N3 duration with Metformin use, linear regression identified a moderate negative correlation between N3 and age in patients taking non-Metformin therapies (R2 = 0.4555). No significant correlations between sleep stage duration and patient sex, smoking status, or body-mass index (BMI) were identified. Conclusion T2DM patients on Metformin had OSA with reduced deep sleep (N3) and REM (Rapid Eye Movement) sleep. These…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.